

Fernando Jerkovich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3036708/publications.pdf>

Version: 2024-02-01

14
papers

182
citations

1478505

6
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

356
citing authors

#	ARTICLE	IF	CITATIONS
1	New approaches for patients with advanced radioiodine-refractory thyroid cancer. <i>World Journal of Clinical Oncology</i> , 2022, 13, 9-27.	2.3	8
2	Exploring the Differences Between Dominant and Nondominant Feet and Hands Bone Mineral Density. <i>Journal of Clinical Densitometry</i> , 2022, 25, 587-591.	1.2	2
3	Asymptomatic elevated parathyroid hormone level due to immunoassay interference. <i>Osteoporosis International</i> , 2021, 32, 2111-2114.	3.1	6
4	Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 315-321.	0.6	3
5	Letter to the Editor: "Foundation One", Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3490-e3491.	3.6	4
6	Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. <i>Endocrine</i> , 2020, 69, 142-148.	2.3	19
7	Impaired bone microarchitecture and strength in patients with tumor-induced osteomalacia. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1502-1509.	2.8	13
8	The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. <i>Endocrine</i> , 2019, 64, 632-638.	2.3	15
9	Rare complications of multikinase inhibitor treatment. <i>Archives of Endocrinology and Metabolism</i> , 2018, 62, 636-640.	0.6	5
10	Impact of historic histopathologic sample review on the risk of recurrence in patients with differentiated thyroid cancer. <i>Archives of Endocrinology and Metabolism</i> , 2018, 62, 157-163.	0.6	3
11	Should Age at Diagnosis Be Included as an Additional Variable in the Risk of Recurrence Classification System in Patients with Differentiated Thyroid Cancer. <i>European Thyroid Journal</i> , 2017, 6, 160-166.	2.4	8
12	Selective use of sorafenib in the treatment of thyroid cancer. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1119.	4.3	54
13	Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. <i>Archives of Endocrinology and Metabolism</i> , 2015, 59, 347-350.	0.6	6
14	Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. <i>Thyroid</i> , 2015, 25, 1235-1242.	4.5	36